CG Oncology Stock Jumps 14% on Positive Phase 3 Bladder Cancer Trial Data

The company said its PIVOT-006 trial cut recurrence risk by 68% and updated the timing and scope of its BCG-unresponsive filing, now expected in March 2027.

Stock market price drop display
Photo: ESB Professional/Shutterstock.com

Key points

  • CG Oncology rose 13.95% Monday, Nov. 16, 2026, to $84.78 after positive PIVOT-006 Phase 3 topline data
  • Trial showed a 68% reduction in recurrence risk (hazard ratio 0.32) versus control
  • No Grade 3 or greater treatment-related adverse events reported
  • Cash and investments together totaled $984.5 million as of Sept. 30, 2026

CG Oncology (Nasdaq: CGON) shares rose 13.95% on Monday, Nov. 16, 2026, closing at $84.78 after a previous close of $74.40, after the company announced positive topline results from its Phase 3 PIVOT-006 trial in an 8-K filed that morning. The S&P 500 ETF (SPY) fell 1.91% over the same session, and volume ran about 10.8 times its usual level.

The trial evaluated adjuvant intravesical cretostimogene in patients with intermediate-risk and high-grade Ta NMIBC following complete tumor resection. The company said the drug reduced the risk of recurrence by 68% compared with the control arm, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001). The median follow-up was 17 months. The company reported no Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations.

Recurrence benefit in a large patient group

The company said there are currently no FDA-approved adjuvant treatment options for the roughly 50,000 patients in this population. The trial enrolled 367 patients across about 90 sites in the United States and Canada.

Filing timelines shift

The company said it plans to submit a second BLA for intermediate-risk and high-grade Ta NMIBC in the second quarter of 2027. Its initial BLA for BCG-unresponsive NMIBC will now also cover high-grade papillary-only disease, with completion expected in March 2027, which the company said reflects FDA feedback. The filing states that all BLA-enabling manufacturing activities for both filings have been completed.

Cash position

As of Sept. 30, 2026, the company reported $28.2 million in cash and equivalents and $956.2 million in short-term investments, or $984.5 million in cash and investments together. For the quarter ended Sept. 30, 2026, it reported an operating loss of $63.2 million, compared with $51.1 million a year earlier.

The company said the topline results will be presented as a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on Dec. 2, 2026.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

Other stock movers this week

CGON page →

Filings, figures and price history are on the CG Oncology page.